Skip to main content

Peer Review reports

From: Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

Original Submission
1 Oct 2017 Submitted Original manuscript
15 Oct 2017 Author responded Author comments - Takeshi Kashiwabara
Resubmission - Version 2
15 Oct 2017 Submitted Manuscript version 2
20 Dec 2017 Reviewed Reviewer Report - David Jarrard
24 Dec 2017 Reviewed Reviewer Report - Shiro Hinotsu
13 Feb 2018 Author responded Author comments - Takeshi Kashiwabara
Resubmission - Version 3
13 Feb 2018 Submitted Manuscript version 3
9 Mar 2018 Reviewed Reviewer Report - Shiro Hinotsu
17 Apr 2018 Author responded Author comments - Takeshi Kashiwabara
Resubmission - Version 4
17 Apr 2018 Submitted Manuscript version 4
23 Apr 2018 Reviewed Reviewer Report - Shiro Hinotsu
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
21 May 2018 Editorially accepted
31 May 2018 Article published 10.1186/s12885-018-4541-0

You can find further information about peer review here.

Back to article page